Soleno Therapeutics Inc Asset Resilience Ratio
Soleno Therapeutics Inc asset resilience ratio. Soleno Therapeutics Inc (SLNO) has an Asset Resilience Ratio of 20.15% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SLNO cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Soleno Therapeutics Inc (2012–2025)
Asset resilience ratio of Soleno Therapeutics Inc from 2012 to 2025. This chart shows how Soleno Therapeutics Inc's Asset Resilience Ratio has changed over time. Read Soleno Therapeutics Inc (SLNO) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Soleno Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Soleno Therapeutics Inc total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $122.57 Million | 20.15% |
| Total Liquid Assets | $122.57 Million | 20.15% |
Asset Resilience Insights
- Good Liquidity Position: Soleno Therapeutics Inc maintains a healthy 20.15% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Soleno Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Soleno Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Soleno Therapeutics Inc Asset Resilience Ratio by Year (2012–2025)
Soleno Therapeutics Inc asset resilience ratio by year from 2012 to 2025. The table below shows the annual Asset Resilience Ratio data for Soleno Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 41.74% | $235.37 Million | $563.83 Million | -19.74pp |
| 2024-12-31 | 61.49% | $203.51 Million | $330.97 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $180.69 Million | -- |
| 2019-12-31 | 0.00% | $0.00 | $38.17 Million | -- |
| 2018-12-31 | 2.27% | $978.00K | $43.15 Million | +2.18pp |
| 2017-12-31 | 0.09% | $35.00K | $39.02 Million | -0.54pp |
| 2016-12-31 | 0.63% | $35.00K | $5.56 Million | +0.20pp |
| 2015-12-31 | 0.43% | $35.00K | $8.20 Million | +0.19pp |
| 2014-12-31 | 0.24% | $20.00K | $8.40 Million | -1.02pp |
| 2013-12-31 | 1.26% | $20.00K | $1.59 Million | +0.46pp |
| 2012-12-31 | 0.80% | $20.00K | $2.51 Million | -- |
About Soleno Therapeutics Inc
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more